Literature DB >> 11062299

Late resolution of diffusion-weighted MRI changes in a patient with prolonged reversible ischemic neurological deficit after thrombolytic therapy.

K Krueger1, H Kugel, M Grond, A Thiel, D Maintz, K Lackner.   

Abstract

BACKGROUND: Reduced apparent diffusion coefficients (ADCs) correlate with cerebral ischemia. The combination of ADC with techniques to measure cerebral perfusion may help to assess the effect of treatment. CASE DESCRIPTION: The authors describe a patient who experienced an acute stroke with hemianopia, consequently treated with intravenous recombinant tissue plasminogen activator. Positron emission tomographic imaging and MRI, including diffusion-weighted MRI, were performed during and shortly after treatment with recombinant tissue plasminogen activator and 34 to 35 hours later. Cerebral perfusion of the left occipital region was reduced to 74%. Diffusion-weighted MRI detected a territory of restricted water movement in the corresponding area. Further magnetic resonance sequences did not show any pathologies. In follow-up, positron emission tomography demonstrated reperfusion. The volume of diffusion and ADC abnormalities detected by MRI decreased markedly. A few hours later, the patient recovered completely. A third MRI examination 10 days later showed normal findings.
CONCLUSIONS: In a patient with prolonged reversible ischemic neurological deficit, resolution of early diffusion changes corresponded to cerebral reperfusion and to the recovery of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062299     DOI: 10.1161/01.str.31.11.2715

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

1.  Reversal of restricted diffusion in cerebral venous thrombosis: case report.

Authors:  D Sarma; R I Farb; D J Mikulis; K G terBrugge
Journal:  Neuroradiology       Date:  2004-01-16       Impact factor: 2.804

2.  Evaluation of small ischemic lesions after carotid artery stenting: the usefulness of thin-slice diffusion-weighted MR imaging.

Authors:  Shigenari Yamatogi; Matakazu Furukawa; Etsushi Iida; Shotaro Takahashi; Hideyuki Ishihara; Shoichi Kato; Michiyasu Suzuki; Naofumi Matsunaga
Journal:  Neuroradiology       Date:  2010-06-29       Impact factor: 2.804

Review 3.  Foundations of advanced magnetic resonance imaging.

Authors:  Roland Bammer; Stefan Skare; Rexford Newbould; Chunlei Liu; Vincent Thijs; Stefan Ropele; David B Clayton; Gunnar Krueger; Michael E Moseley; Gary H Glover
Journal:  NeuroRx       Date:  2005-04

4.  Magnetic resonance restricted diffusion resolution correlates with clinical improvement and response to treatment in herpes simplex encephalitis.

Authors:  Joshua L Duckworth; Jason S Hawley; Gerard Riedy; Mark E Landau
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  MR and clinical follow-up of diffusion-weighted cerebral lesions after carotid artery stenting.

Authors:  Elke A M Hauth; Christian Jansen; Robert Drescher; Michael Schwartz; Michael Forsting; Horst J Jaeger; Klaus D Mathias
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

6.  Transparent color-coded three-dimensional diffusion-weighted magnetic resonance imaging for the numerical analysis of reversible and irreversible hyperacute ischemic stroke--case report.

Authors:  T Satoh; M Omi; C Ohsako; C Ekino
Journal:  Neuroradiology       Date:  2005-04-02       Impact factor: 2.804

7.  Sodium MRI and the assessment of irreversible tissue damage during hyper-acute stroke.

Authors:  Fernando E Boada; Yongxian Qian; Edwin Nemoto; Tudor Jovin; Charles Jungreis; S C Jones; Jonathan Weimer; Vincent Lee
Journal:  Transl Stroke Res       Date:  2012-05-04       Impact factor: 6.829

Review 8.  Silent Cerebral Events after Atrial Fibrillation Ablation - Overview and Current Data.

Authors:  Thomas Deneke; Karin Nentwich; Joachim Krug; Patrick Müller; Peter Hubert Grewe; Andreas Mügge; Anja Schade
Journal:  J Atr Fibrillation       Date:  2014-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.